<Á¦ 15ȸ °¡¿Í»ç³¢º´ ½ÉÆ÷Áö¿ò (¿Â¶óÀÎ) >
Session I : °¡¿Í»ç³¢º´ÀÇ ÇöÀç ÁÂÀå: ÇÑÁöȯ(°¡Å縯ÀÇ´ë)
13:00~13:25 Àü±¹ ¼Ò¾ÆÃ»¼Ò³â °ü»óµ¿¸Æ Á÷°æ Á¤»óÄ¡ Á¶»ç Áß°£º¸°í À¯Á¤Áø(¿ï»êÀÇ´ë)
13:25~13:50 ºÒÀÀ¼º °¡¿Í»ç³¢º´ÀÇ Ä¡·á·Î Infliximab »ç¿ëÀÇ Àӻ󿬱¸ ¼Û¹Î¼·(ÀÎÁ¦ÀÇ´ë)
13:50~14:15 ÃÖ±ÙÀÇ Ä¡·á°æÇâ À±°æ¸²(°æÈñÀÇ´ë)
14:15~14:40 Risk factor related to coronary outcome ±è¼öÁø(¿¬¼¼ÀÇ´ë)
14:40~15:00 Discussion
15:00~15:15 Break time
Session II : What is COVID-19 associated MIS-C? ÁÂÀå: ÃÖÁ¾¿î(ºÐ´çÁ¦»ýº´¿ø)
15:15~15:40 ±¹³»¿Ü MIS-C Àǽɻç·Ê º¸°í °ûÁöÈñ(¼º±Õ°üÀÇ´ë)
15:40~16:05 Pathogenesis of MIS-C À̼ö¿µ(°¡Å縯ÀÇ´ë)
16:05~16:30 Clinical guidance of MIS-C ÀÌÇöÁÖ(¼¿ïÀÇ´ë)
16:30~16:50 Discussion
16:50~17:00 Æóȸ»ç ºÎȸÀå: ¼Û¹Î¼·(ÀÎÁ¦ÀÇ´ë)